Update of antispike severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) monoclonal antibodies (Record no. 18273)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | a |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20221118113328.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 221118b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 19140 |
| Author | Chatterjee, Suparna |
| 245 ## - TITLE STATEMENT | |
| Title | Update of antispike severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) monoclonal antibodies |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol.54(1), Jan-Feb |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mumbai |
| Name of publisher, distributor, etc. | Wolter Kluwer |
| Year | 2022 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 51-57p. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS‑CoV‑2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of nonhospitalized COVID‑19 patients with mild‑to‑moderate disease at high risk of disease progression. This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high cost of these biologics may make it unaffordable for many patients, but further clinical studies on their cost‑benefit profile shall provide useful information to the scientific community and patients. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4774 |
| Topical term or geographic name entry element | PHARMACOLOGY |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 19141 |
| Co-Author | Choudhury, Shouvik |
| 773 0# - HOST ITEM ENTRY | |
| Place, publisher, and date of publication | Andheri - Mumbai Wolters Kluwer India Private Limited |
| International Standard Serial Number | 0253-7613 |
| Title | Indian Journal of Pharmacology |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| URL | https://www.ijp-online.com/temp/IndianJPharmacol54151-2105218_055052.pdf |
| Link text | Click here |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Permanent Location | Current Location | Shelving location | Date acquired | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| School of Pharmacy | School of Pharmacy | Archieval Section | 2022-11-18 | 2022-2152 | 2022-11-18 | 2022-11-18 | Articles Abstract Database |